Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 11;11(9):1348.
doi: 10.3390/cancers11091348.

18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis

Riccardo Laudicella  1 , Domenico Albano  2 , Pierpaolo Alongi  3 , Giovanni Argiroffi  4 , Matteo Bauckneht  5 , Sergio Baldari  6 , Francesco Bertagna  7 , Michele Boero  8 , Giuseppe De Vincentis  9 , Angelo Del Sole  10 , Giuseppe Rubini  11 , Lorenzo Fantechi  12 , Viviana Frantellizzi  13 , Gloria Ganduscio  14 , Priscilla Guglielmo  15 , Anna Giulia Nappi  16 , Laura Evangelista  17 ; on the behalf of Young AIMN Working Group  18
Affiliations
Review

18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis

Riccardo Laudicella et al. Cancers (Basel). .

Abstract

Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid (anti-[18F]-FACBC) has been approved for the detection of prostate cancer (PCa) in patients with elevated prostate-specific-antigen following prior treatment. This review and meta-analysis aimed to investigate the diagnostic performance of 18F-FACBC positron emission tomography/computed-tomography (PET/CT) in the detection of primary/recurrent PCa. A bibliographic search was performed including several databases, using the following terms: "FACBC"/"fluciclovine" AND "prostate cancer"/"prostate" AND "PET"/"Positron Emission Tomography". Fifteen and 9 studies were included in the systematic reviews and meta-analysis, respectively. At patient-based analysis, the pooled sensitivity and specificity of 18F-FACBC-PET/CT for the assessment of PCa were 86.3% and 75.9%, respectively. The pooled diagnostic odds-ratio value was 16.453, with heterogeneity of 30%. At the regional-based-analysis, the pooled sensitivity of 18F-FACBC-PET/CT for the evaluation of primary/recurrent disease in the prostatic bed was higher than in the extra-prostatic regions (90.4% vs. 76.5%, respectively); conversely, the pooled specificity was higher for the evaluation of extra-prostatic region than the prostatic bed (89% vs. 45%, respectively). 18F-FACBC-PET/CT seems to be promising in recurrent PCa, particularly for the evaluation of the prostatic bed. Additional studies to evaluate its utility in clinical routine are mandatory.

Keywords: 18F-FACBC; PET/CT; meta-analysis; prostate cancer; recurrence; review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow-chart.
Figure 2
Figure 2
QUADAS 2 score of all included studies.
See this image and copyright information in PMC

References

    1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015;65:87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016;66:7–30. doi: 10.3322/caac.21332. - DOI - PubMed
    1. Kim M.M., Hoffman K.E., Levy L.B., Frank S.J., Pugh T.J., Choi S., Nguyen Q.N., McGuire S.E., Lee A.K., Kuban D.A. Improvement in prostate cancer survival over time: A 20-year analysis. Cancer J. 2012;18:1–8. doi: 10.1097/PPO.0b013e3182467419. - DOI - PubMed
    1. Bruce J.Y., Lang J.M., McNeel D.G., Liu G. Current controversies in the management of biochemical failure in prostate cancer. Clin. Adv. Hematol. Oncol. 2012;10:716–722. - PubMed
    1. Roehl K.A., Han M., Ramos C.G., Antenor J.A.V., Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: Long-term results. J. Urol. 2004;172:910–914. doi: 10.1097/01.ju.0000134888.22332.bb. - DOI - PubMed